Business Description
Axogen Inc
ISIN : US05463X1063
Total Employee Number:
622Compare
Compare
Traded in other countries / regions
AXGN.USAAXGN.Mexico0HKD.UKLT3.Germany IPO Date
2026-08-19Description
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.55 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.99 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 33.09 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.1 | |||||
3-Year FCF Growth Rate | 51.1 | |||||
3-Year Book Growth Rate | 4.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 53.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.88 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.6 | |||||
Quick Ratio | 5.04 | |||||
Cash Ratio | 3.67 | |||||
Days Inventory | 243.43 | |||||
Days Sales Outstanding | 42.84 | |||||
Days Payable | 16.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | -4.05 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.56 | |||||
Operating Margin % | -5.12 | |||||
Net Margin % | -13.36 | |||||
EBITDA Margin % | -8.08 | |||||
ROE % | -19.44 | |||||
ROA % | -13.55 | |||||
ROIC % | -7.91 | |||||
3-Year ROIIC % | 51.45 | |||||
ROC (Joel Greenblatt) % | -19.31 | |||||
ROCE % | -13.29 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 132.53 | |||||
PS Ratio | 10.05 | |||||
PB Ratio | 10.54 | |||||
Price-to-Tangible-Book | 10.85 | |||||
Price-to-Free-Cash-Flow | 396.54 | |||||
Price-to-Operating-Cash-Flow | 170.14 | |||||
EV-to-EBIT | -89.05 | |||||
EV-to-EBITDA | -128.9 | |||||
EV-to-Revenue | 10.42 | |||||
EV-to-Forward-Revenue | 9.36 | |||||
EV-to-FCF | 401.86 | |||||
Price-to-GF-Value | 0.5 | |||||
Price-to-Median-PS-Value | 1.94 | |||||
| Price-to-Net-Current-Asset-Value | 17.8 | |||||
| Price-to-Net-Cash | 43.05 | |||||
Earnings Yield (Greenblatt) % | -1.12 | |||||
FCF Yield % | 0.24 | |||||
Forward Rate of Return (Yacktman) % | -30.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Axogen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 800.66 - 800.66 | ||
| Shares Outstanding (Mil) | 53.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axogen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Axogen Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 08:00 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:00 | -- | ||
| Second quarter earnings results for 2026 | 2026-07-29 | -- | ||
| General meeting for 2026 | 2026-06-23 08:30 | -- | ||
| Guidance call for 2026 | 2026-05-13 09:35 | -- | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:00 | -- | ||
| First quarter earnings results for 2026 | 2026-04-28 | -- | ||
| The Citizens Life Sciences Conference | 2026-03-10 12:30 | -- | ||
| Leerink Global Healthcare Conference | 2026-03-09 13:00 | -- |
Show
Entries
Axogen Inc Frequently Asked Questions
What is Axogen Inc(MEX:AXGN)'s stock price today?
The current price of MEX:AXGN is MXN800.66. The 52 week high of MEX:AXGN is MXN800.66 and 52 week low is MXN800.66.
When is next earnings date of Axogen Inc(MEX:AXGN)?
The next earnings date of Axogen Inc(MEX:AXGN) is 2026-10-29 Est..
Does Axogen Inc(MEX:AXGN) pay dividends? If so, how much?
Axogen Inc(MEX:AXGN) does not pay dividend.
Press Release
Articles on Axogen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers